Form 4: Aveanna Healthcare Holdings Insider Robert M. Williams Jr. Reports Stock Sales
SEC Form 4 Filing
Robert M. Williams Jr., a director of Aveanna Healthcare Holdings, reported the sale of common stock through entities associated with J.H. Whitney Capital Partners, LLC, under a pre-arranged trading plan.
Summary
- Robert M. Williams Jr., a director of Aveanna Healthcare Holdings, Inc. (AVAH), reported the sale of common stock on May 12 and 13, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on December 13, 2024, by J.H. Whitney VII, L.P. and affiliated entities.
- On May 12, 2025, 30,429 shares were sold at a weighted average price of $5.72, with prices ranging from $5.62 to $5.84.
- On May 13, 2025, 27,883 shares were sold at a weighted average price of $5.86, with prices ranging from $5.84 to $5.89.
- Additional sales were made by PSA Healthcare Investment Holding LLC, JHW Iliad Holdings LLC, PSA Iliad Holdings LLC, and JHW Iliad Holdings II LLC.
- Williams disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any positive or negative outlook.
Industry Context
Insider sales are a common occurrence, and the use of a pre-arranged trading plan (Rule 10b5-1) is a legal and transparent way for insiders to sell shares without raising concerns about trading on non-public information. The size and frequency of these sales can be compared to those of peers in the healthcare services industry to assess whether they are typical or indicative of a larger trend.
Comparison to Industry Standards
- It's common for executives and directors to utilize 10b5-1 trading plans to diversify their holdings or for personal financial planning.
- Comparing the size of these transactions to similar transactions by insiders at companies like Option Care Health (OPCH) or Addus HomeCare (ADUS) could provide context.
- The weighted average prices of $5.72 and $5.86 can be benchmarked against the average trading volume and price volatility of Aveanna Healthcare (AVAH) to assess the impact of these sales on the market.
Stakeholder Impact
- The stock sales by a director could potentially create short-term downward pressure on the stock price.
- Shareholders may interpret insider sales as a lack of confidence in the company's future prospects, although the use of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 12/13/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 05/12/2025 | Date of first reported transaction (sale of shares) |
| 05/13/2025 | Date of second reported transaction (sale of shares) |
| 05/14/2025 | Date of Form 4 filing |
Keywords
Form 4, insider trading, stock sale, Aveanna Healthcare Holdings, AVAH, Robert M. Williams Jr., J.H. Whitney Capital Partners, Rule 10b5-1 trading plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.